Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding the vesting of awards under the GlaxoSmithKline Share Value Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of equity award vesting and does not contain financial performance data.
Material Changes
The filing details the conclusion of the three-year vesting period for awards made in 2008, which ended on December 31, 2010. On February 19, 2011, the following shares vested for specific PDMRs:
- Mr S M Bicknell: 2,520 shares
- Mr D S Redfern: 3,350 shares
- Ms C Thomas: 2,520 shares
- Mrs V A Whyte: 1,200 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the disclosure of the share vesting transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares vested for PDMRs on February 19, 2011.
- Confirm the vesting schedule completion date for the 2008 Share Value Plan awards (December 31, 2010).
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.